Finoriq research workspace

Arcturus Therapeutics Holdings Inc. (ARCT) Company Overview

Arcturus Therapeutics Holdings Inc. also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for. Review ARCT filings, fundamentals, valuation, and ownership on Finoriq.

Company Snapshot

Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; and ARCT-810 (LUNAR-OTC), which is in Phase 2 clinical development to address ornithine transcarbamylase (OTC) deficiency. In addition, it develops KOSTAIVE, a self-amplifying RNA vaccine for COVID-19; ARCT-2138 (LUNAR-FLU), which is in Phase1 clinical trial for the treatment of seasonal influenza; and ARCT-2304 (LUNAR-H5N1) that is in Phase1 clinical trial for the treatment of Pandemic Influenza. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Company

Arcturus Therapeutics Holdings Inc. (ARCT)

Ticker

ARCT

Market Cap

$170.8M

Latest Price

$6.01

Industry

Biotech & Pharma

Open insider transactions

Arcturus Therapeutics Holdings Inc. (ARCT) Current Valuation Metrics

Static valuation preview for Arcturus Therapeutics Holdings Inc. (ARCT). Market data retrieved 2026-07-09. Filing currency USD.

Live data loads in the app

This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.